Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center...

Area of Science:

• Hematology
• Oncology
• Clinical Therapeutics

Background:

• Pomalidomide, a third-generation immunomodulatory drug (IMiD), is effective in relapsed/refractory multiple myeloma (RRMM).
• The combination of pomalidomide, cyclophosphamide, and dexamethasone (PCd) is being investigated for RRMM treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of the PCd regimen in patients with relapsed/refractory multiple myeloma.
• To identify factors influencing treatment outcomes in RRMM patients receiving PCd.

Main Methods:

• Retrospective analysis of 45 RRMM patients treated with PCd.
• Patients received at least one prior therapy and had experienced disease progression.
• Outcomes assessed included overall response rate (ORR), disease control rate (DCR), time to treatment not-given (TTNT), progression-free survival (PFS), and overall survival (OS).

Main Results:

• The PCd regimen achieved an ORR of 46.7% and a DCR of 66.7%.
• Median TTNT, PFS, and OS were 14.6, 9.0, and 21.0 months, respectively.
• High-risk cytogenetics were associated with worse PFS and DCR. Neutropenia was the most frequent severe toxicity.

Conclusions:

• The addition of cyclophosphamide to pomalidomide and dexamethasone (PCd) demonstrates promising efficacy in pretreated RRMM patients.
• PCd represents a viable therapeutic option in real-world settings for RRMM.
• Further investigation into PCd's role in RRMM management is warranted.